US FDA to hold off action on weight-loss drug copies pending court ruling
The health regulator announced last month that there was no longer a shortage of Novo's Wegovy and diabetes drug Ozempic, ...
Ivim Health Supports the Outsourcing Facilities Association's Appeal of Court Ruling That Further Restricts Access to Compounded GLP-1 Medications
Ivim Health (Ivim), a leading telehealth platform comprised of obesity medicine physicians and nurse practitioners, joins the ...
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Endpoints News14h
Com­pounders’ mo­tion for pre­lim­i­nary in­junc­tion de­nied in case over tirzepatide short­age
Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide ...
MarketBeat on MSN16h
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
Indian Pharma Companies Set to Launch Generic Diabetes Medicines At 90% Lower Price
With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...